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   Serum hCG and’ AFP for testicular germ cell turnors， PSAP for prostatic carcinoma， and serum
CEA and P2 MG for urogenital malignanc：ies were measured by radioimmunoassay （RIA） techniques．
1． Specific tumor marker
   1） hCG and AFP： AFP was detected in embryon’al carcinema （EC）， infantile EC and terato－
carcinoma．（TC）1．AFP and／or hqG was detected in the mixed type of tu皿or consisting of EC・TC
and choriocarqinoma． This was dependerit on the major histological component ef the tu血or． Even
in the pure seminoma， elevation of hCG was noted in 4 out of 17 cases， followed by normalization
after orchiectotny． Alteration of AFP and hCG well demonstrated an effect of treatment and clinical
courses． Reelevation of the markers revealed an advance of clinical staging and recurrence of the
tumor．
   2） PSAP： Serum levels of PSAP by RIA method correiated well with those by enzYme method，
however， the． former showed pseudonegative values ・less than the latter． Elevation of PSAP gave
a clue to the initial diagnosis and to earlier detection of recurrence of prostatic carcinoma．
2． Nonspecific tumor marker
   1） Beta－2－MG： Since the elevation of P2 MG prilnarily reflects a decrease in the renal function，
relationship between creatinine clearance （GFR） and P2 MG in noncancerous patients with a variety
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．of renal function was applied to the cancer patients and such a functional factor to increase serum
level of P2 MG was excluded． Elevation of P2 MG was seen in paticnts with advanced stage of uro－
genital malignancies． Such’?rate of elevation was 62．50／． in testicular carcinoma， 55．60／，’ in tenal cell
carcinoma， 48．！％ in bladder carcinoma， 45．50／． in pelvic and ureteral ’tumors and 22．20／． in prostatic
carcinoma． Beta－2－MG increased in 46．90／， of advanced urogenital canc¢rs．as a whole．
  2） CEA： CEA also elevated in．the advanced stage of urogenital cancers， although its percentage
was less than that in B2 MG． Elevation of CEA was detected in 44．40／． of prostatic carcinomas， 37．00／o
ofbladder carcinomas， 36．40／． ofpelvic and ureteral tumors and 22．20／． of renal． ceil carcinomas． None
of testicular carcinoma revealed an． abnor血a1〔氾A value．
  3）’ Combination of P2 MG andfor CEA did not raise positive rates of the markers in each of uro－
genital cancers． However， when those patients i4rcre divided into 3 groups such as “Alive” with no
evidence of disease， “Alive” with disease and “Dead”， according to the survivai states， elevation of
P2 MG or P2MG and CEA was seep in patients in whom tumorous lesions were not eliminated or re－
currence was noticed， indicating a poor prognosis．
  In conclusion， to estimate AFP and hCG or PSAP， as h specific tumor marker，・ and P2 MG andfor
CEA， as a nonspecific tumor marker，’@is a useful adjunct to detect dlinical coUrses and to predict prog－
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Table 1． Hist’ological classification and AFP and hCG qstimation





















































































































・x．・ SEM ：Seminoma； EC：Embryonal carcinoma；






















                 Log Y ＝2．012 ’ O， S749 ［og X
                 r＝一〇，9787
， n＝looiiiiii＝．             ．   PくO．001
’；三饒ii載”＝1．                ●NQrma量 renal function
   ’：il，1．1．［，1｝lts／Sjis， e Decreased rer；at function
      ：Zlll’iljncut’ ．，． ：．：：，．． Variation range
       ’＝～1賓……灘三、．  ．．撫，ac・。・di・g t。 th・剛
          礪上音
                     ’＝……ii懇
Fig．
       a5 1 2 3 45 10 se
            Serum B2 Micregtobutin （pgimO
1． Relationship between serurn fi2 microglobulin and endogenous
   creatinine clearance in noncancerous patients

























した．CEAはCEA IRE SORIN KIT（CISキッ
ト・フランス）5）を用いて，正常域は10 ng／ml以下
である．
       3．成     績
1） AFP， hCG
 Table 1には摘出睾丸腫瘍の組織別にAFP， h（〕G
の陽性率（AFP＜long／ml， hcGく6．6mIu／ml）を






embryonal carcinoma （EC）， infantile EC， terato－
carcinoma（TC）では全例にAFPが陽性で， hCGは
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Table 3．Clinical staging and elevation of AFP and hCG in sera
of patients with testicular carcinoma
PatientsAFP＞ 10 ng／ml hCG＞6．6 mlU／ml
Stage 1 26 4（ 15．4％） 3（11．5％）
Stage l1 2 2（100．0％） 1 （’50．0％）
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陽性率を検討した（Table 3）． stage ．1に比べてstage
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Fig． 3． Serum prostatic acid phosphatase levels
    according to the clinical staging of
    prostatlc carclnoma
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Table 4． lncidehce of elevation of P2 microglobulin in patients with urogenital malignancies
No．of ElevatedNo． of Patients Elevated
Patients’ No．in the’ advaneed stageNo．






















Tota1 90 30｛33．3％｝ 64 30（46．9％）


































































． production of f12 MG （n＝4G）
   tog y＝ log 2．85 ＋O，16 log x
   r＝o．44， p〈o，ps
O      o
θ   亨
。
 ・’＝蟷。：s●
      o   コ  。蟹8畢・
      0  ％   o





   1 5 10 20 so 1co 2co 500
           CEA （hgtmt）
Fig． 4． Relationship between carcinoembryonic
    antigen and P2 microglobulin
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Table 6． lncidence of eievation of P2 microglobulin （P2 MG） and／or CEA in patients ・
     with Urogenital Malignancies of the advanced stage
     （十）： elevated ；（一）： within normal limits
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No． of
PatientsCEA（十）B2 MG（一）CEA（一）B2 MG｛十）CEA（ 一一 ） Gt MG（十）
Biadder carcinoma27
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Table 8． lncidence of positive plasma CEA in urogenital malignancies
Laurence Reynoso Wechsler Kawamura
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